0001127602-20-026862.txt : 20201013
0001127602-20-026862.hdr.sgml : 20201013
20201013162007
ACCESSION NUMBER: 0001127602-20-026862
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200915
FILED AS OF DATE: 20201013
DATE AS OF CHANGE: 20201013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spears Michael P
CENTRAL INDEX KEY: 0001667779
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33462
FILM NUMBER: 201236511
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSULET CORP
CENTRAL INDEX KEY: 0001145197
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 043523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
BUSINESS PHONE: 978-600-7000
MAIL ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-09-15
0001145197
INSULET CORP
PODD
0001667779
Spears Michael P
C/O INSULET CORPORATION
100 NAGOG PARK
ACTON
MA
01720
1
SVP, RA and Compliance
Common Stock
2020-09-15
5
G
0
E
2500
0
D
8947
D
Common Stock
2020-10-09
4
M
0
13350
29.87
A
22297
D
Common Stock
2020-10-09
4
M
0
8907
29.26
A
31204
D
Common Stock
2020-10-09
4
S
0
22257
246.10
D
8947
D
Employee Stock Option (Right to Buy)
29.87
2020-10-09
4
M
0
13350
0
D
2025-07-27
Common Stock
13350
0
D
Employee Stock Option (Right to Buy)
29.26
2020-10-09
4
M
0
8907
0
D
2026-02-24
Common Stock
8907
3735
D
The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $244.63 to $251.38. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
/s/ John W. Kapples, attorney-in-fact
2020-10-13